Atripla Co-pay Program to Cover More People

Gilead Sciences and Bristol-Myers Squibb have announced that the co-payment assistance program for Atripla (containing efavirenz, tenofovir and emtricitabine) has been revised and will essentially benefit all people living with HIV with private health insurance who pay any out-of-pocket co-payment fees. The greatly enhanced co-payment program went into effect July 1.

Previously, the program—which can reduce a person’s out-of-pocket co-payment at the pharmacy by $200—didn’t kick in until after a person had paid the first $50 of his or her co-pay. As most people with private health insurance have individual drug co-payments of less than $50, many privately insured individuals using Atripla weren’t able to benefit from the program. Now the program will cover a person’s co-payment beginning with the first dollar, widely expanding the number of people who are eligible for this assistance.

As before, the program will cover up to $200 of a person’s co-payment each month. The program is limited to people with private health insurance.

The Friends of AIDS Foundation is dedicated to enhancing the quality of life for HIV positive individuals and empowering people to make healthy choices to prevent the spread of the HIV virus. To learn more about The Friends of AIDS Foundation, please visit: http://www.friendsofaids.org.


Together We Remain Strong!